Dietary Propionate, Gut Microbiota, Parkinson’s & ECS: Research

Research Review:

The study in this review gained publication on March 26th in Cell Reports, a journal known for publishing high-quality Research across the Life Sciences.

"Metabolic rescue of α-synuclein-induced neurodegeneration through propionate supplementation and intestine-neuron signaling in C. elegans"

This Research, led by Professor Chaogu Zheng at The University of Hong Kong, offers groundbreaking insights into how propionate, a type of short-chain fatty acid (SCFA), could potentially provide a new approach to treating Parkinson's Disease (PD) and possibly other neurodegenerative conditions. The intensive paper delves into the intricate communication between the intestine and the brain, uncovering that propionate can play a pivotal role in suppressing neurodegeneration in PD by influencing this interorgan signaling.

The core discovery is that in PD models, the presence of lower propionate levels correlates with the disease's progression. The study found a significant reversal of PD-associated adverse effects on gene expression and energy production within the intestine by inhibiting propionate's breakdown or increasing its levels through dietary means.

This change promoted neuronal health without directly addressing the protein aggregates commonly targeted in PD treatment. The Research highlights a novel perspective on treating neurodegenerative diseases.

It emphasizes the potential of targeting metabolic pathways and the gut-brain axis rather than focusing solely on the protein aggregates in the brain. This approach aligns with growing evidence suggesting the significant role of gut-derived metabolites in brain health.

In practical terms, the study suggests that PD patients might benefit from dietary adjustments aimed at increasing propionate levels, such as incorporating more fiber-rich foods to enhance gut bacteria's SCFA production. This insight opens the door to non-pharmacological strategies that complement existing treatments and potentially lead to more effective management of PD and other neurodegenerative diseases.

Summation concerning the Endocannabinoid System:

Increasing propionate levels through dietary means, like incorporating more fiber-rich foods to boost gut bacteria's production of short-chain fatty acids (SCFAs), including propionate, is indeed connected to beneficial health outcomes. This connection impacts the gut-brain axis, immune function, and metabolic health. The relationship between propionate and endogenous cannabinoids involves complex interactions within the body's metabolic and physiological processes.

Endogenous cannabinoids, part of the endocannabinoid system (ECS), play a crucial role in regulating appetite, pain sensation, mood, and memory. The ECS consists of cannabinoid receptors (such as CB1 and CB2), endogenous cannabinoids (endocannabinoids), and enzymes responsible for the synthesis and degradation of endocannabinoids.

Fatty acid amide hydrolase (FAAH) is one of the primary enzymes involved in the degradation of endocannabinoids, such as anandamide (AEA). Inhibiting FAAH can lead to increased levels of endocannabinoids, which might have therapeutic benefits, including reduced anxiety, improved mood, and decreased pain sensation.

The interaction between dietary propionate and the ECS, particularly regarding FAAH activity and endocannabinoid levels, is a subject of ongoing Research. Some studies suggest that SCFAs, including propionate, influence the ECS by modulating the gut microbiome, which could affect the systemic levels of endocannabinoids. The gut microbiome interacts with the ECS and can influence its activity directly and indirectly.

However, direct evidence linking increased propionate levels through dietary fiber to specific changes in FAAH activity or endogenous cannabinoid production is not as straightforward.

The effects of propionate and other SCFAs on the ECS likely depend on a complex interplay of factors, including the composition of the gut microbiota, dietary patterns, genetic factors, and individual metabolic health.

Specific insights into how propionate affects FAAH or the synthesis of endogenous cannabinoids will require further Research and targeted studies. Such studies would help clarify the precise mechanisms by which dietary components like fiber-rich foods could influence the ECS and overall health.

In summary, while there is a conceptual basis for the interaction between dietary propionate, the gut microbiome, and the ECS, the direct effects on FAAH and endogenous cannabinoid production require more detailed investigation to understand their implications for health and disease management fully.

© Mike Robinson, Founder Global Cannabinoid Researcher Center and Creator of ECS Balance Control, The Researcher OG

References:

Reviewed Research: Metabolic rescue of α-synuclein-induced neurodegeneration through propionate supplementation and intestine-neuron signaling in C. elegans Wang, Yang, Liu, Zheng Feb.26, 2024 DOI: https://doi.org/10.1016/j.celrep.2024.113865

Piomelli, D. The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 4, 873–884 (2003). https://doi.org/10.1038/nrn1247

Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, Wilkie GD, Austin BJ, Patricelli MP, Cravatt BF. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5044-9. doi: 10.1073/pnas.97.10.5044. PMID: 10805767; PMCID: PMC25778

Kerbrat A, Ferré JC, Fillatre P, Ronzière T, Vannier S, Carsin-Nicol B, Lavoué S, Vérin M, Gauvrit JY, Le Tulzo Y, Edan G. Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase. N Engl J Med. 2016 Nov 3;375(18):1717-1725. doi: 10.1056/NEJMoa1604221. PMID: 27806235.